Determination of medication cutoff values in a pain patient population

Journal of Opioid Management

Volumn 7, Issue 2, 2011, Pages 117-122

  Pesce, Amadeo ^a   West, Cameron ^a   West, Robert ^a   Crews, Bridgit ^a   Mikel, Charles ^a   Rosenthal, Murray ^a   Almazon, Perla ^a   Latyshev, Sergey ^a  

^a Millennium Research Institute   (United States)

Author keywords

Cutoffs; LC MS MS; Pain patients; Patient compliance; Urine drug testing

Indexed keywords

BUPRENORPHINE; CARISOPRODOL; CREATININE; DEXTROPROPOXYPHENE; DRUG METABOLITE; HYDROCODONE; HYDROMORPHONE; MEPROBAMATE; METHADONE; MORPHINE; OPIATE; OXYMORPHONE; PETHIDINE; TRAMADOL;

ARTICLE; CALIBRATION; CHRONIC PAIN; CREATININE BLOOD LEVEL; DRUG EXCRETION; DRUG THERAPY; DRUG URINE LEVEL; HUMAN; IMMUNOASSAY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PATIENT MONITORING; POPULATION RESEARCH; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY;

ANALGESICS, OPIOID; CHROMATOGRAPHY, LIQUID; CHRONIC DISEASE; HUMANS; MEDICATION ADHERENCE; PAIN; RETROSPECTIVE STUDIES; TANDEM MASS SPECTROMETRY;

EID: 79955937217     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2011.0054     Document Type: Article

References (20)

1. Horowitz GL, Altaie S, Boyd JC, et al.: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory: Approved Guideline. 3rd ed. Wayne, PA: CLSI, 2008.
2. Holler JM, Levine B: Testing of non-Samhsa drugs in alcohol and drugs of abuse testing. In Dasgupta A (ed.): Critical Issues in Alcohol and Drug Abuse Testing. Washington, DC: AACC Press, 2010: 163-181.
3. Cone EJ, Caplan YH, Black DL, et al.: Urine drug testing of chronic pain patients: Licit and illicit drug patterns. J Anal Toxicol. 2008; 32: 530-543.
4. White RM, Black ML: Pain Management Testing Reference. Washington, DC: AACC Press, 2008: 204-208.
5. Gourlet D, Heit HA: The art and science of urine drug testing. Clin J Pain. 2010; 26: 358.
6. Mikel C, Almazan P, West R, et al.: LC-MS/MS extends the range of drug analysis in pain patients. Ther Drug Monit. 2009; 31: 746-748.
7. West R, Pesce A, West C, et al.: Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in a pain management population. Pain Physician. 2010; 13: 71-78.
8. Pesce A, West C, West R, et al.: Reference intervals: A novel approach to detecting drug abuse in a pain patient population. J Opioid Manag. 2010; 6: 341-350.
9. Pesce A, West C, West R, et al.: Marijuana correlates with use of other illicit drugs in a pain patient population. Pain Physician. 2010; 13: 283-287.
10. Wu AHB: Urine adulteration before testing for drugs of abuse. In Shaw LN, Kwong TC (eds.): The Clinical Toxicology Laboratory: Contemporary Practice of Poisoning Evaluation. Washington, DC: AACC Press, 2001: Chapter 11, 157-171.
11. Horn PA, Pesce AJ: Reference Intervals: A User's Guide. Washington, DC: AACC Press, 2005.
12. Horn P: Reference intervals and clinical decision limits. In Kaplan L, Pesce A (eds.): Clinical Chemistry: Theory, Analysis, Correlation. 5th ed. St. Louis, MO: Mosby/Elsevier. 2010: 439-455.
13. Federation of State Medical Boards of the United States, Inc.: Model policy for the use of controlled substances for the treatment of pain; May 2004. Available at http://www.fsmb.org/pdf/2004-grpol-Controlled-Substances.pdf. Accessed May 25, 2010.
14. Manchikanti L, Manchukonda R, Pampati V, et al.: Evaluation of abuse of prescription and illicit drugs in chronic pain patients receiving short acting (hydrocodone) or long acting (methadone) opioids. Pain Physician. 2005; 8: 257-261. (Pubitemid 41131536)
15. Manchikanti L, Manchukonda R, Pampati V, et al.: Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician. 2006; 9: 123-129.
16. Manchikanti L, Cash KA, Damron KS, et al.: Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables. Pain Physician. 2006; 9: 215-226. (Pubitemid 44227394)
17. Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2): 113-130.
18. Nafziger AN, Bertino JS: Utility and application of urine drug testing in chronic pain management with opioids. Clin J Pain. 2009; 25: 73-79.
19. Reisfield GM, Salazar E, Bertholf RL: Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci. 2007; 37: 301-314. (Pubitemid 350105930)
20. Hattab EM, Goldberger BA, Johannsen LM, et al.: Modification of screening immunoassays to detect sub-threshold concentrations of cocaine, cannabinoids, and opiates in urine: Use for detecting maternal and neonatal drug exposures. Ann Clin Lab Sci. 2000; 30(1): 85-91. (Pubitemid 30078310)